IDEAYA Biosciences
7000 Shoreline Court
Suite 350
South San Francisco
California
94080
United States
Tel: 650-443-6209
Website: http://www.ideayabio.com/
About IDEAYA Biosciences
Founded in 2015, IDEAYA Biosciences is a public, clinical-stage synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using DNA sequencing and other molecular diagnostics. Our approach integrates extensive capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from the therapies we are developing. We are applying these capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality – which represents an emerging class of precision medicine targets. We believe this diversified approach will enable us to deliver the right medicine to the right patient to drive a more robust clinical response.
Stock Symbol: IDYA
109 articles with IDEAYA Biosciences
-
IDEAYA Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
5/10/2022
IDEAYA Biosciences, Inc. provided a business update and announced financial results for the first quarter ended March 31, 2022.
-
IDEAYA Biosciences to Participate in Investor Conferences in May 2022
5/3/2022
IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in investor conferences in May 2022.
-
IDEAYA Biosciences Receives Orphan Drug Designation for Darovasertib, a PKC Inhibitor, for the Treatment of Uveal Melanoma
5/2/2022
IDEAYA Biosciences, Inc. announced that the U.S. Food and Drug Administration has granted orphan-drug designation to darovasertib, a potential first-in-class protein kinase C inhibitor, for the treatment of uveal melanoma.
-
IDEAYA Biosciences Appoints Catherine Mackey, Ph.D., to its Board of Directors
4/6/2022
IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the appointment of Catherine Mackey, Ph.D., to its Board of Directors.
-
IDEAYA Biosciences Reports IDE397 Interim Phase 1 Clinical Data
3/15/2022
IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced interim Phase 1 clinical data for IDE397, a potential best in class methionine adenosyltransferase 2a inhibitor.
-
IDEAYA Biosciences, Inc. Reports 2021 Financial Results and Provides Business Update
3/15/2022
IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the year ended December 31, 2021.
-
IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreements for Evaluation of Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma and Additional cMET-Driven Tumors
3/14/2022
IDEAYA Biosciences, Inc. announced that it has entered into additional clinical trial collaboration and supply agreements with Pfizer Inc. to support further evaluation of darovasertib and crizotinib combination therapy in a Phase 2 potential registration-enabling clinical trial in patients with metastatic uveal melanoma and in a Phase 1 clinical trial in patients with cMET-driven tumors, such as hepatocellular carcinoma and/or non-small cell lung cancer.
-
Pfizer will cease operations within Russia and proceeds from its subsidiary in that country will be donated to provide direct humanitarian support to the people of Ukraine.
-
IDEAYA Biosciences Announces Investor Webcast to Report Interim IDE397 Phase 1 Clinical Data and Corporate Update
3/8/2022
IDEAYA Biosciences, Inc. announced plans to issue a pre-market press release and host an Investor Webcast on Tuesday, March 15, 2022 to discuss interim clinical data for IDE397, a potential best-in-class MAT2A inhibitor being evaluated in a Phase 1 Clinical Trial in patients having tumors with MTAP deletion.
-
IDEAYA Biosciences to Participate in Investor Conferences in March 2022
3/1/2022
IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in investor conferences in March 2022.
-
IDEAYA Biosciences to Participate in Investor Conferences in February 2022
2/1/2022
IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in an investor conference in February 2022.
-
IDEAYA Advances First-in-Class PARG Development Candidate, IDE161, into IND-Enabling Studies and Exercises Option with Cancer Research UK and University of Manchester for Exclusive Worldwide License
1/31/2022
IDEAYA Biosciences, Inc. announced initiation of IND-enabling studies for IDE161, a potential first-in-class PARG inhibitor development candidate.
-
IDEAYA Biosciences Announces Corporate and Portfolio Update for J.P. Morgan 40th Annual Healthcare Conference
1/10/2022
IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced corporate and portfolio updates in connection with its participation in the J.P. Morgan Annual Healthcare Conference.
-
IDEAYA Biosciences Announces Acquisition of Proprietary INQUIRE™ Chemical Library to Enhance Synthetic Lethality Drug Discovery Platform
1/5/2022
IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, reported the acquisition of its INQUIRE™ Chemical Library to enhance the company's synthetic lethality drug discovery platform.
-
IDEAYA Biosciences Appoints Dr. Frank McCormick as Chair of Scientific Advisory Board
1/4/2022
IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the appointment of Frank McCormick, Ph.D., FRS, to Chair of the IDEAYA Scientific Advisory Board.
-
IDEAYA Biosciences to Participate in Investor Conferences in January 2022
1/3/2022
IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in investor conferences in January 2022.
-
IDEAYA Reports Clinical Data from Phase 2 Expansion Dose of Darovasertib and Crizotinib Synthetic Lethal Combination in Heavily Pre-Treated Metastatic Uveal Melanoma
12/7/2021
IDEAYA Biosciences, Inc. provided a clinical data update for the Phase 1/2 trial evaluating darovasertib and crizotinib synthetic lethal combination in metastatic uveal melanoma (MUM) patients.
-
IDEAYA Biosciences to Participate in Investor Conferences in December 2021
11/30/2021
IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in investor conferences in December 2021.
-
IDEAYA Announces Investor Webcast to Review Clinical Data from Phase 1/2 Trial of Darovasertib Combination with Crizotinib in Metastatic Uveal Melanoma
11/29/2021
IDEAYA Biosciences, Inc. announced its plans for a clinical data update on December 7, 2021, including plans to issue a pre-market press release and host a conference call and webcast to discuss clinical data from the ongoing Phase 1/2 trial evaluating darovasertib and crizotinib combination in patients with metastatic uveal melanoma .
-
IDEAYA Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update
11/15/2021
IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the third quarter ended September 30, 2021.